FDA Approves Sanofi’s Rapid Acting Insulin Biosimilar Merilog for Diabetes
Meilog marks the first rapid-acting insulin biosimilar to gain FDA approval for the treatment of diabetes.
August 16, 2026
Meilog marks the first rapid-acting insulin biosimilar to gain FDA approval for the treatment of diabetes.